Global HIV Antivirals Market Size study, By Product (Fixed Dose Combinations (FDCs), Integrase Strand Transfer Inhibitors (INSTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2028

BIZ4983405
200 Pages
July 2022
Pharmaceuticals

Download Sample Get Discount

Global HIV Antivirals Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The HIV Antivirals refers to antiretroviral medicines utilized to hinder the ability of the human immunodeficiency virus (HIV) to multiply in the body. HIV Antivirals are organized into six different classes based on the stage of the HIV life cycle. The US Food and Drug Administration (FDA) approved more than two dozen antiretroviral drugs to treat HIV infection. The growing prevalence of HIV infection and increasing awareness towards HIV treatment options as well as recent product launches and approvals from regulatory authorities are factors that are accelerating the global market demand. For instance, according to World Health Organization (WHO) estimates – as of 2020, 37.7 million individuals were living with HIV. Around 6,80,000 people succumbs to HIV and another 1.5 million individuals acquired HIV. Moreover, as per United Nations Children's Fund (UNICEF) - in 2020, Globally around 1.72 million children aged 0-14 living with HIV. However, only 54 per cent children received life-saving antiretroviral therapy (ART). Furthermore, other recent factors including new product announcements & recent regulatory approvals are likely to influence the growth of Global HIV Antivirals Market. For instance, in July 2020, the U.S. Food and Drug Administration approved North Carolina, US based ViiV Healthcare’s new antiretroviral medication named Rukobia (fostemsavir), intended for adults living with HIV. In addition, in June 2022, Mumbai, India based Cipla Ltd. in collaboration with Geneva, Switzerland based not-for-profit R&D Organization, Drugs for Neglected Diseases initiative (DNDi) launched a new fixed-dose combination of four antiretroviral (ARV) treatment for children living with HIV in South Africa. This new treatment combination is composed of abacavir, lamivudine, lopinavir, and ritonavir and intended for infants and young children. Also, growing healthcare infrastructure in emerging economies and favorable government initiatives across the globe are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, limited access to HIV treatment and rigorous regulatory guidelines for approval of HIV drugs impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global HIV Antivirals Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising government funded programs and presence of recent medications approvals in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing healthcare sector and increasing incidences of HIV infections in the region, would create lucrative growth prospects for the global HIV Antivirals Market across the Asia Pacific region.

Major market players included in this report are:

ViiV Healthcare

Gilead Sciences, Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Johnson & Johnson

Genetech, Inc.

Teva Pharmaceutical Industries Ltd.

AbbVie

Cipla

Pfizer Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

Fixed Dose Combinations (FDCs)

Integrase Strand Transfer Inhibitors (INSTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Entry Inhibitors - CCR5 co-receptor antagonist

Protease Inhibitors (PIs)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020

Base year – 2021

Forecast period – 2022 to 2028

Target Audience of the Global HIV Antivirals Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

1.1. Market Snapshot

1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)

1.2.1. Global HIV Antivirals Market, by Region, 2020-2028 (USD Million)

1.2.2. Global HIV Antivirals Market, by Product, 2020-2028 (USD Million)

1.2.3. Global HIV Antivirals Market, by Distribution Channel, 2020-2028 (USD Million)

1.3. Key Trends

1.4. Estimation Methodology

1.5. Research Assumption

Chapter 2. Global HIV Antivirals Market Definition and Scope

2.1. Objective of the Study

2.2. Market Definition & Scope

2.2.1. Scope of the Study

2.2.2. Industry Evolution

2.3. Years Considered for the Study

2.4. Currency Conversion Rates

Chapter 3. Global HIV Antivirals Market Dynamics

3.1. HIV Antivirals Market Impact Analysis (2020-2028)

3.1.1. Market Drivers

3.1.1.1. Growing prevalence of HIV infection.

3.1.1.2. Increasing awareness towards HIV treatment options.

3.1.1.3. Recent product launches and approvals from regulatory authorities

3.1.2. Market Challenges

3.1.2.1. Limited access to HIV treatment

3.1.2.2. Rigorous regulatory guidelines for approval of HIV drugs.

3.1.3. Market Opportunities

3.1.3.1. Growing healthcare infrastructure in emerging economies.

3.1.3.2. Favourable government initiatives across the globe.

Chapter 4. Global HIV Antivirals Market Industry Analysis

4.1. Porter’s 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)

4.2. PEST Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.3. Investment Adoption Model

4.4. Analyst Recommendation & Conclusion

4.5. Top investment opportunity

4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

5.1.1. Assessment of the overall impact of COVID-19 on the industry

5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global HIV Antivirals Market, by Product

6.1. Market Snapshot

6.2. Global HIV Antivirals Market by Product, Performance - Potential Analysis

6.3. Global HIV Antivirals Market Estimates & Forecasts by Product 2018-2028 (USD Million)

6.4. HIV Antivirals Market, Sub Segment Analysis

6.4.1. Fixed Dose Combinations (FDCs)

6.4.2. Integrase Strand Transfer Inhibitors (INSTIs)

6.4.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

6.4.4. Entry Inhibitors - CCR5 co-receptor antagonist

6.4.5. Protease Inhibitors (PIs)

6.4.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

6.4.7. Others

Chapter 7. Global HIV Antivirals Market, by Distribution Channel

7.1. Market Snapshot

7.2. Global HIV Antivirals Market by Distribution Channel, Performance - Potential Analysis

7.3. Global HIV Antivirals Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)

7.4. HIV Antivirals Market, Sub Segment Analysis

7.4.1. Hospital Pharmacies

7.4.2. Retail Pharmacies

7.4.3. Online Pharmacies

Chapter 8. Global HIV Antivirals Market, Regional Analysis

8.1. HIV Antivirals Market, Regional Market Snapshot

8.2. North America HIV Antivirals Market

8.2.1. U.S. HIV Antivirals Market

8.2.1.1. Product estimates & forecasts, 2018-2028

8.2.1.2. Distribution Channel estimates & forecasts, 2018-2028

8.2.2. Canada HIV Antivirals Market

8.3. Europe HIV Antivirals Market Snapshot

8.3.1. U.K. HIV Antivirals Market

8.3.2. Germany HIV Antivirals Market

8.3.3. France HIV Antivirals Market

8.3.4. Spain HIV Antivirals Market

8.3.5. Italy HIV Antivirals Market

8.3.6. Rest of Europe HIV Antivirals Market

8.4. Asia-Pacific HIV Antivirals Market Snapshot

8.4.1. China HIV Antivirals Market

8.4.2. India HIV Antivirals Market

8.4.3. Japan HIV Antivirals Market

8.4.4. Australia HIV Antivirals Market

8.4.5. South Korea HIV Antivirals Market

8.4.6. Rest of Asia Pacific HIV Antivirals Market

8.5. Latin America HIV Antivirals Market Snapshot

8.5.1. Brazil HIV Antivirals Market

8.5.2. Mexico HIV Antivirals Market

8.6. Rest of The World HIV Antivirals Market

Chapter 9. Competitive Intelligence

9.1. Top Market Strategies

9.2. Company Profiles

9.2.1. ViiV Healthcare

9.2.1.1. Key Information

9.2.1.2. Overview

9.2.1.3. Financial (Subject to Data Availability)

9.2.1.4. Product Summary

9.2.1.5. Recent Developments

9.2.2. Gilead Sciences, Inc.

9.2.3. GlaxoSmithKline plc

9.2.4. Merck & Co., Inc.

9.2.5. Johnson & Johnson

9.2.6. Genetech, Inc.

9.2.7. Teva Pharmaceutical Industries Ltd.

9.2.8. AbbVie

9.2.9. Cipla

9.2.10. Pfizer Inc.

Chapter 10. Research Process

10.1. Research Process

10.1.1. Data Mining

10.1.2. Analysis

10.1.3. Market Estimation

10.1.4. Validation

10.1.5. Publishing

10.2. Research Attributes

10.3. Research Assumption

List of Tables

TABLE 1. Global HIV Antivirals Market, report scope

TABLE 2. Global HIV Antivirals Market estimates & forecasts by Region 2018-2028 (USD Million)

TABLE 3. Global HIV Antivirals Market estimates & forecasts by Product 2018-2028 (USD Million)

TABLE 4. Global HIV Antivirals Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)

TABLE 5. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 6. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 7. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 8. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 9. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 10. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 11. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 12. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 13. Global HIV Antivirals Market by segment, estimates & forecasts, 2018-2028 (USD Million)

TABLE 14. Global HIV Antivirals Market by region, estimates & forecasts, 2018-2028 (USD Million)

TABLE 15. U.S. HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 16. U.S. HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 17. U.S. HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 18. Canada HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 19. Canada HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 20. Canada HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 21. UK HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 22. UK HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 23. UK HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 24. Germany HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 25. Germany HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 26. Germany HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 27. RoE HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 28. RoE HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 29. RoE HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 30. China HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 31. China HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 32. China HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 33. India HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 34. India HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 35. India HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 36. Japan HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 37. Japan HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 38. Japan HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 39. RoAPAC HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 40. RoAPAC HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 41. RoAPAC HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 42. Brazil HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 43. Brazil HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 44. Brazil HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 45. Mexico HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 46. Mexico HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 47. Mexico HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 48. RoLA HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 49. RoLA HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 50. RoLA HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 51. Row HIV Antivirals Market estimates & forecasts, 2018-2028 (USD Million)

TABLE 52. Row HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 53. Row HIV Antivirals Market estimates & forecasts by segment 2018-2028 (USD Million)

TABLE 54. List of secondary sources, used in the study of global HIV Antivirals Market

TABLE 55. List of primary sources, used in the study of global HIV Antivirals Market

TABLE 56. Years considered for the study

TABLE 57. Exchange rates considered

Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Contact Us

Drop Us an email at

Similar Reports

Client Testimonials

Maria

David

Sara